Scientific Advisory Board

Ron dePinho, Scientific Advisor at Tvardi Therapeutic, Houston TX

Ron DePinho, M.D.

Co-Founder of Tvardi & Professor and Past President MD Anderson Cancer Center

Ronald Depinho, M.D. has had a distinguished career in cancer research including his role as President of the University of Texas, MD Anderson Cancer Center. During his tenure as MD Anderson’s president, Dr. DePinho conceived and launched the Cancer Moon Shots Program, maintained MD Anderson’s top ranking, dramatically enhanced its research and training excellence, recruited many world class faculty, and expanded its global network to reach one-third of the human population. His research program has made fundamental contributions to our understanding and treatment of cancer, aging and degenerative disorders. He is a member of the National Academy of Science and National Academy of Medicine and recipient of honorary degrees and many awards including the Ellis Island Medal of Honor and knighthood from Portugal. Dr. DePinho has successfully founded and raised capital for numerous biotech companies including publicly traded Aveo and Karyopharm. He was an advisor for biotech firms, Epizyme and Agios as well as Abbott and GSK. He holds an M.D. from Albert Einstein College of Medicine and a B.S. from Fordham University.

David Tweady, Scientific Advisor at Tvardi Therapeutic, Houston TX

David Tweardy, M.D.

Co-Founder of Tvardi & Division Head, Internal Medicine, MD Anderson Cancer Center

David Tweardy, M.D. is Head of the Division of Internal Medicine at MD Anderson Cancer Center and a physician-scientist recognized for his contributions to our understanding of the biochemistry and molecular and cellular biology of signal transducer and activator of transcription (STAT) 3, as well as its contribution to inflammation, fibrosis, and oncogenesis. His group claims several firsts in the STAT3 field, including the identification, molecular cloning, and full characterization of the β isoform of human STAT3, identifying the contribution of STAT3 to human oncogenesis, and discovering competitive small-molecule inhibitors of STAT3 through targeting its Src homology (SH) 2 domain. He has obtained $15M in non-dilutive funding to support development of small-molecule STAT3 inhibitors from concept to Phase I testing. Dr. Tweardy is the major inventor of all patents licensed to or owned by Tvardi. Dr. Tweardy received his M.D. at Harvard Medical School and an A.B. in Chemistry from Princeton University.

Scientific Advisor, Scientific Advisor at Tvardi Therapeutic, Houston TX

Keith T. Flaherty, M.D

Professor, Medicine, Harvard Medical School & Director of Developmental Therapeutics, Massachusetts General Hospital Cancer Center

Dr. Flaherty is the director of the Henri and Belinda Termeer Center for Targeted Therapy, director of Clinical Research at the Massachusetts General Hospital Cancer Center, and Professor of Medicine at Harvard Medical School. As described in the more than 250 peer reviewed primary research reports he has authored or co-authored, Dr. Flaherty and colleagues made several seminal observations recently that have defined the treatment of melanoma when they established the efficacy of BRAF, MEK and combined BRAF/MEK inhibition in patients with metastatic melanoma in a series of New England Journal of Medicine articles for which Dr. Flaherty was the first author. Dr. Flaherty also has been a leader in assessing and identifying mechanisms of de novo and acquired resistance to BRAF inhibitor therapy and clinically evaluating next generation inhibitors, work that has had implications for resistance to targeted therapy regimens used to treat other malignant diseases. Dr. Flaherty has received extensive NCI funding support with K12, K23, SPORE, RO1, U54 and PO1 grants. He serves as editor-in-chief of Clinical Cancer Research. He is the principal investigator of the NCI MATCH trial, the first NCI-sponsored trial assigning patients to targeted therapy independent of tumor type on the basis of DNA sequencing detection of oncogenes. He has made major commitments to ECOG as chair of the Developmental Therapeutics Committee and in 2013 was appointed as ECOG Deputy Chair for Biomarker Science.

Scientific Board Adviso Ravi Thadhani

Ravi I. Thadhani, M.D., MPH

Chief Academic Officer, Partners HealthCare & Professor of Medicine, Harvard Medical School

Dr. Thadhani MD, MPH is the Chief Academic Officer of Partners HealthCare and Professor of Medicine at Harvard Medical School. Dr. Thadhani has two major areas of interest: medical complications of pregnancy (preeclampsia and gestational diabetes) and vitamin D metabolism. He is also an expert in the science and management of cachexia in medical conditions such as chronic kidney disease (CKD). His goals are to translate biological discoveries into novel diagnostics and therapies for humans. In the area of preeclampsia, his collaborations with basic scientists have led to novel diagnostic tests now available in Europe and are being tested in the U.S., and of late, first-in-human clinical trials to prolong pregnancy in women with severe preterm preeclampsia. In the area of vitamin D metabolism, he has performed observational studies, collaborated with basic scientists in animal experimental studies, and translated these findings to multinational randomized trials to test several hypotheses in humans.

More recently, he and collaborators put forward another paradigm-changing concept related to bioavailable vitamin D, potentially changing our view of who truly is vitamin D deficient. Dr. Thadhani has mentored several fellows and junior faculty members, all of who have had a strong track record of publications and grant support, and many of who are on faculty at leading institutions around the country. Dr. Thadhani has served as a reviewer for and has published in several journals including New England Journal of Medicine, Journal of American Medical Association, Lancet, Proc National Academy of Science, Circulation, Journal of America Society of Nephrology, and Kidney International. He is an inducted member into the American Society of Clinical Investigation, the American Epidemiology Society and the Association of American Physicians. He is the recipient of numerous awards and honors including the Alumni Award of Merit from the Harvard School of Public Health and the Harold Amos Faculty Diversity Award, Harvard Medical School.

Michael T. Lewis, Ph.D.

Co-Founder of Tvardi & Professor, Molecular and Cellular Biology and Radiology, Baylor College of Medicine

Dr. Lewis, Ph.D. is a Professor in the Departments of Molecular and Cellular Biology and Radiology, and a member of the Lester and Sue Smith Breast Center at Baylor College of Medicine (BCM). Dr. Lewis has expertise in breast development and breast cancer, with a focus on the identification and regulation of tumor-initiating cells and the goal of identifying new vulnerabilities in these cells that can be targeted therapeutically. As part of this work, he developed one of the largest human breast cancer patient-derived xenograft (PDX) renewable tissue resources available, a resource used worldwide for evaluation of experimental therapeutics in the area of breast oncology. Dr. Lewis also co-founded and is the President and CEO of StemMed, Ltd from which Tvardi Therapeutics was spun out. He studied biology at the College of William and Mary and received his doctoral degree from the University of California, Santa Cruz.

We use cookies to ensure that we give you the best experience on our website. By using this website you agree to the Privacy Policy and  Terms of Use.